Literature DB >> 15608490

Anaplastic pleomorphic xanthoastrocytomas. Review of the literature with reference to malignancy potential.

Ismail H Tekkök1, Aydin Sav.   

Abstract

Malignancy potential of pleomorphic xanthoastrocytomas (PXAs) has rather been an underestimated reality. We report the case of a 13-year-old boy who presented with signs of increased intracranial pressure. The child had been epileptic since the age of 2. Computed tomography and magnetic resonance scans revealed a huge left frontal mass. At surgery, a subtotal excision was accomplished. Histopathological diagnosis was anaplastic PXA (grade III; WHO, 2000). The tumor showed an increased mitotic index and minimal endothelial proliferation. The patient died 3.5 months later due to a fatal intracranial hemorrhage. A review of the entire PXA literature revealed 15 well-documented cases of PXA with subsequent malignant transformation and 11 cases of primary anaplastic PXA. The prognosis was grim for both subsets of patients. Anaplastic PXAs clearly represent the transition between the original PXA concept and lipidized giant-cell glioblastoma. Copyright 2004 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2004        PMID: 15608490     DOI: 10.1159/000081935

Source DB:  PubMed          Journal:  Pediatr Neurosurg        ISSN: 1016-2291            Impact factor:   1.162


  11 in total

1.  Atrial fibrillation as an uncommon presentation in a large pleomorphic xanthoastrocytoma.

Authors:  Sadettin Sezer; Ali Baykan; Ebru Yilmaz; Ekrem Unal; Sertaç Hanedan Onan; Ali Yikilmaz; Kazım Uzum; Mehmet Akif Ozdemir; Nazmi Narin
Journal:  Childs Nerv Syst       Date:  2011-11-16       Impact factor: 1.475

2.  Hemorrhage in pleomorphic xanthoastrocytomas.

Authors:  Ismail H Tekkök
Journal:  J Neurooncol       Date:  2005-11-15       Impact factor: 4.130

3.  Pleomorphic Xanthoastrocytoma: Natural History and Long-Term Follow-Up.

Authors:  Cristiane M Ida; Fausto J Rodriguez; Peter C Burger; Alissa A Caron; Sarah M Jenkins; Grant M Spears; Dawn L Aranguren; Daniel H Lachance; Caterina Giannini
Journal:  Brain Pathol       Date:  2014-12-05       Impact factor: 6.508

4.  Anaplastic PXA in adults: case series with clinicopathologic and molecular features.

Authors:  Yao Schmidt; B K Kleinschmidt-DeMasters; Dara L Aisner; Kevin O Lillehei; Denise Damek
Journal:  J Neurooncol       Date:  2012-10-25       Impact factor: 4.130

5.  Patterns of care and outcomes of patients with pleomorphic xanthoastrocytoma: a SEER analysis.

Authors:  Stephanie M Perkins; Nandita Mitra; Wan Fei; Eric T Shinohara
Journal:  J Neurooncol       Date:  2012-07-28       Impact factor: 4.130

6.  Pleomorphic xanthoastrocytoma of childhood: MR imaging and diffusion MR imaging features.

Authors:  W Moore; D Mathis; L Gargan; D C Bowers; L J Klesse; L Margraf; K Koral
Journal:  AJNR Am J Neuroradiol       Date:  2014-07-03       Impact factor: 3.825

Review 7.  Primary anaplastic pleomorphic xanthoastrocytoma with widespread neuroaxis dissemination at diagnosis--a pediatric case report and review of the literature.

Authors:  Toshiyuki Okazaki; Teruyoshi Kageji; Kazuhito Matsuzaki; Hidehisa Horiguchi; Takanori Hirose; Hiroyoshi Watanabe; Toshihiro Ohnishi; Shinji Nagahiro
Journal:  J Neurooncol       Date:  2009-03-27       Impact factor: 4.130

8.  Epithelioid GBMs show a high percentage of BRAF V600E mutation.

Authors:  Bette Kay Kleinschmidt-DeMasters; Dara L Aisner; Diane K Birks; Nicholas K Foreman
Journal:  Am J Surg Pathol       Date:  2013-05       Impact factor: 6.394

9.  Pleomorphic xanthoastrocytoma with anaplastic features: A rare case report and review of literature with reference to current management.

Authors:  M R Patibandla; Madhukar Nayak; A K Purohit; Amit Kumar Thotakura; Megha Uppin; Sundaram Challa
Journal:  Asian J Neurosurg       Date:  2016 Jul-Sep

10.  Intraventricular Anaplastic Pleomorphic Xanthoastrocytoma: Very Rare Localization and Early Recurrence of a Rare Tumor.

Authors:  Fabio Roberti; Martin Baggenstos
Journal:  Cureus       Date:  2018-05-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.